Skip to main content

Animations

MJFF Publications

1711 - 1720 of 5662 Results
Title
Year
  • Year
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • OPEN
    Title: Pathological α-syn aggregation is mediated by glycosphingolipid chain length and the physiological state of α-syn in vivo
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1073/pnas.2108489118
    Citation Count: 25
  • OPEN
    Title: [18F]Nifene PET/CT Imaging in Mice: Improved Methods and Preliminary Studies of α4β2* Nicotinic Acetylcholinergic Receptors in Transgenic A53T Mouse Model of α-Synucleinopathy and Post-Mortem Human Parkinson’s Disease
    Journal Name: Molecules
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/molecules26237360
    Citation Count: 14
  • OPEN
    Title: How Parkinson’s patients in the USA perceive deep brain stimulation in the 21st century: Results of a nationwide survey
    Journal Name: Journal of Clinical Neuroscience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.jocn.2021.11.017
    Best OA location URL:
    Citation Count: 5
  • OPEN
    Title: White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2021.11.007
    Citation Count: 37
  • OPEN
    Title: Atlas of RNA editing events affecting protein expression in aged and Alzheimer’s disease human brain tissue
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41467-021-27204-9
    Citation Count: 32
  • OPEN
    Title: Different rates of cognitive decline in autosomal dominant and late‐onset Alzheimer disease
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/alz.12505
    Citation Count: 6
  • OPEN
    Title: Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson’s Disease: Focus on Neuroinflammation
    Journal Name: Molecular Neurobiology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s12035-021-02625-1
    Best OA location URL:
    Citation Count: 10
  • OPEN
    Title: Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000013121
    Citation Count: 62
  • OPEN
    Title: The contribution of behavioral features to caregiver burden in FTLD spectrum disorders
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/alz.12494
    Citation Count: 14
  • OPEN
    Title: A Downsized and Optimised Intracellular Library-Derived Peptide Prevents Alpha-Synuclein Primary Nucleation and Toxicity Without Impacting Upon Lipid Binding
    Journal Name: Journal of Molecular Biology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.jmb.2021.167323
    Citation Count: 8
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.